GHRP-2 (Growth Hormone Releasing Peptide 2) is a synthetic hexapeptide that activates the ghrelin receptor to stimulate GH release from the pituitary. It's one of the oldest and most extensively studied GHRPs, with a more potent GH pulse than Ipamorelin but a less clean side effect profile — including meaningful cortisol and prolactin elevation that Ipamorelin avoids. Understanding these trade-offs is essential for choosing the right GHRP for any given research protocol.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
GHRP-2 is used to stimulate growth hormone release from the pituitary, primarily for body composition enhancement (increased lean mass, fat loss), recovery, and anti-aging applications. It's also used medically as a diagnostic tool for GH axis testing. Its stronger GH pulse amplitude compared to Ipamorelin makes it preferred in some research protocols despite its less clean side effect profile. GHRP-2, like Ipamorelin, activates the ghrelin receptor (GHSR-1a) in the pituitary. GHRP-2 has been studied since the early 1990s and has more published human data than most research peptides — partly because it was investigated as a diagnostic tool for assessing GH axis function. **Intense hunger:** GHRP-2 activates ghrelin receptors — ghrelin is a potent appetite stimulant. Elevated cortisol is catabolic — counteracting some of the benefits of GH elevation for body composition. A single GHRP-2 injection reliably stimulates GH release, making it useful for provocative testing in suspected GH deficiency.
How Does GHRP-2 Work?
GHRP-2, like Ipamorelin, activates the ghrelin receptor (GHSR-1a) in the pituitary. The binding to GHSR-1a triggers pulsatile GH release — the same mechanism as Ipamorelin. The key difference is receptor selectivity. GHRP-2 is less selective than Ipamorelin, producing off-target stimulation of corticotroph cells (elevating cortisol and ACTH) and lactotroph cells (elevating prolactin) alongside GH release.
This reduced selectivity has two consequences: GHRP-2 can produce a slightly larger GH pulse than Ipamorelin in some research subjects (because the cortisol/ACTH co-stimulation adds to the overall stress response that includes GH), but it also produces the cortisol and prolactin elevation that make longer-term use more complicated. Elevated cortisol is catabolic — counteracting some of the benefits of GH elevation for body composition. Elevated prolactin can cause mood effects and libido suppression.
Despite these drawbacks, GHRP-2 remains widely used, particularly in research contexts where maximum GH pulse amplitude is the goal rather than clean long-term optimisation.
Research Evidence
GHRP-2 has been studied since the early 1990s and has more published human data than most research peptides — partly because it was investigated as a diagnostic tool for assessing GH axis function. A single GHRP-2 injection reliably stimulates GH release, making it useful for provocative testing in suspected GH deficiency.
Body composition research with GHRP-2 shows effects consistent with GH elevation: increased lean mass, reduced fat mass, improved recovery. Clinical research also confirmed the cortisol and prolactin elevation issue at standard doses.
The combination of GHRP-2 + GHRH (either endogenous stimulation or exogenous GHRH analogs like CJC-1295) produces the largest GH pulses achievable with secretagogue peptides — larger than either GHRP or GHRH analog alone. This synergistic combination is why many research protocols pair a GHRP with a GHRH analog.
What Is the Recommended GHRP-2 Dosage?
| Protocol | Dose | Route | Timing | Notes |
|---|---|---|---|---|
| Standard | 100–200 mcg | SubQ | Fasted, 3x daily | Standard research dose |
| Diagnostic GH test | 1 mcg/kg body weight | IV or SubQ | Single dose | Medical provocative test |
| Combined with CJC-1295 | 100 mcg each | SubQ | Same injection, fasted | Synergistic GH pulse |
| High pulse (maximum GH) | 200–300 mcg | SubQ | Fasted | More side effects at this range |
What Are the Side Effects of GHRP-2?
**Cortisol elevation:** GHRP-2's most clinically significant drawback. Cortisol is elevated meaningfully with each injection — more so than Ipamorelin. For short-term or intermittent use this is manageable, but for daily long-term protocols the chronic cortisol exposure may offset GH benefits for body composition.
**Prolactin elevation:** Mild prolactin increase with GHRP-2 use. At research doses this rarely produces clinically significant effects, but can contribute to mild libido suppression or mood changes in sensitive individuals. Monitoring prolactin levels with long-term use is advisable.
**Intense hunger:** GHRP-2 activates ghrelin receptors — ghrelin is a potent appetite stimulant. Many users report significant hunger within 30 minutes of injection. More pronounced than with Ipamorelin. This can be advantageous for those trying to increase caloric intake and problematic for those managing weight.
**Water retention:** Standard for all GH secretagogues. Generally resolves after adaptation phase.
**Ipamorelin comparison:** For protocols focused on clean long-term GH optimisation, Ipamorelin is the preferred choice. GHRP-2 is better suited for short-term maximum GH stimulation or research protocols where the cortisol/prolactin effects are acceptable trade-offs for higher peak GH.
GHRP-2 vs GHRP-6: Key Differences
While both GHRP-2 and GHRP-6 activate the same ghrelin receptor (GHSR-1a), they differ significantly in their practical effects and user experience. Understanding these differences is critical for protocol selection.
| Feature | GHRP-2 | GHRP-6 |
|---|---|---|
| GH Pulse Magnitude | Very strong (larger than GHRP-6) | Strong (comparable to GHRP-2) |
| Appetite Stimulation | Mild to moderate | Intense (primary effect) |
| Cortisol Elevation | Significant | Significant (similar level) |
| Prolactin Elevation | Moderate | Moderate (similar) |
| Practical Use Case | Maximum GH pulse priority | Appetite stimulation goal |
| Best Protocol | Short-term, high-frequency dosing | With meals to utilise hunger effect |
GHRP-2's slightly larger GH pulse and more moderate appetite effect make it the choice when GH maximisation is the primary goal. GHRP-6's intense hunger becomes the defining characteristic — useful for hardgainers but problematic for weight management. Both have been substantially replaced by Ipamorelin in modern research due to Ipamorelin's superior selectivity and minimal side effects.
Stacking GHRP-2 with GHRH Analogs
The most powerful approach to GH stimulation in research protocols involves stacking a GHRP (like GHRP-2) with a GHRH analog (like CJC-1295 or Sermorelin). This combination produces synergistic GH pulses far exceeding either compound alone.
How the Combination Works
GHRP-2 and GHRH analogs work on completely different receptor pathways. GHRP-2 activates the ghrelin receptor (GHSR-1a) in somatotroph cells, while GHRH analogs activate GHRH receptors. When both pathways are stimulated simultaneously, the GH release amplification is non-linear — meaning the combined effect is substantially greater than the sum of the individual effects.
Research data shows that the GH pulse from combined GHRP-2 + GHRH can be 2-3 times larger than either compound alone. This is why this combination is so prevalent in research protocols despite the increased cortisol and prolactin elevation.
Dosing for Combined Protocols
Standard stacking protocols use 100 mcg of GHRP-2 with 100 mcg of CJC-1295, injected subcutaneously in the same syringe or as two separate injections at the same time. Both should be administered in a fasted state (2+ hours of fasting) to maximise GH response. The protocol typically runs 2-3 times daily, with the most important injection being pre-sleep to amplify the natural nocturnal GH pulse.
Some advanced protocols use even higher doses (up to 300 mcg of GHRP-2) when maximum GH pulses are the goal, but this dramatically increases cortisol and prolactin elevation. Most research suggests 100-200 mcg is the sweet spot for balancing GH elevation with manageable side effects.
GHRP-2 Receptor Selectivity and Off-Target Effects
Understanding the mechanistic basis of GHRP-2's side effect profile requires looking at receptor selectivity. GHRP-2 binds the ghrelin receptor with high affinity, but this receptor is expressed in multiple cell types throughout the pituitary and hypothalamus.
In **somatotroph cells**, GHRP-2 activation triggers GH release — the desired effect. However, the same receptor is also expressed in **corticotroph cells** (which produce ACTH and cortisol) and **lactotroph cells** (which produce prolactin). GHRP-2's broad activation across these cell types produces the cortisol and prolactin elevation that accompanies GH release.
Ipamorelin's development specifically aimed to improve receptor selectivity — it preferentially activates somatotroph cells with much less off-target corticotroph and lactotroph stimulation. This is why Ipamorelin produces clean GH pulses without the cortisol and prolactin elevation of GHRP-2.
The trade-off for GHRP-2's reduced selectivity is a slightly larger GH pulse amplitude. Whether this trade-off is worth it depends entirely on the protocol goals. For short-term maximum GH stimulation, GHRP-2 has an advantage. For long-term optimisation, Ipamorelin's selectivity is superior.
Dosing Schedule Strategies
GHRP-2 protocols vary significantly depending on whether the goal is diagnostic testing, maximum acute GH elevation, or longer-term optimisation. The short half-life (15-30 minutes) means that timing and frequency are critical.
Pre-Workout Injection
Many protocols include a pre-workout GHRP-2 injection (100-200 mcg) 15-30 minutes before resistance training. The rationale is that elevated GH during the workout and immediate post-workout window enhances anabolic signaling. This should be combined with a fasted state or a long fast (3+ hours) to avoid glucose suppression of GH.
Pre-Sleep Injection
The pre-sleep injection is considered the most important in most protocols. GH naturally pulses during deep sleep, particularly in the first 2-3 hours after sleep onset. An GHRP-2 injection 30-60 minutes before bed amplifies this natural pulse. The dose is typically 100-200 mcg, and sleep quality often improves in the first week (though some users report restlessness initially).
Mid-Morning Injection
Some protocols include a third injection in the mid-morning, again in a fasted state. This takes advantage of another natural GH pulse window. Dosing is the same as other injections (100-200 mcg).
Frequency and Cycling
Research protocols typically run daily dosing for 4-12 weeks, followed by a break. The cortisol elevation with longer-term use suggests that continuous daily dosing may not be optimal for chronic protocols. Some advanced researchers use "pulsatile" protocols — injecting 5-6 days per week with 1-2 days off per week to allow cortisol and prolactin normalisation.
Comparison with Other GH Secretagogues
The GH secretagogue class includes multiple compounds with different mechanisms, selectivity profiles, and practical advantages. GHRP-2 is just one option within this broader landscape.
GHRP-2 vs Ipamorelin
Ipamorelin is arguably the most commonly used GHRP in modern research due to its superior selectivity and minimal cortisol/prolactin effects. GHRP-2 produces a slightly larger GH pulse but comes with the cost of off-target hormone elevation. For most long-term protocols, Ipamorelin is the preferred choice. GHRP-2 remains relevant for short-term maximum GH stimulation or diagnostic testing.
GHRP-2 vs MK-677
MK-677 is an oral GH secretagogue that also activates ghrelin receptors. It has a 24-hour half-life, meaning once-daily dosing versus GHRP-2's multiple daily injections. MK-677 causes significant appetite stimulation and water retention, similar to GHRP-2. The advantage of MK-677 is convenience (oral, no injection), but it provides less precise pulse timing. GHRP-2 allows targeted pulsatile stimulation (pre-workout, pre-sleep, etc.), while MK-677 is more of a chronic elevation approach.
GHRP-2 vs CJC-1295 Alone
CJC-1295 (a GHRH analog) works on a different pathway than GHRP-2. While CJC-1295 produces robust GH release through GHRH receptor activation, combining it with GHRP-2 produces non-linear synergy — the combined GH pulse is far larger than either alone. CJC-1295 typically has minimal side effects (no cortisol or prolactin elevation), so pairing it with GHRP-2 is often used to "ride" the large GH pulse amplification while managing the side effect burden with careful dosing.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
GHRP-2 is used to stimulate growth hormone release from the pituitary, primarily for body composition enhancement (increased lean mass, fat loss), recovery, and anti-aging applications. It's also used medically as a diagnostic tool for GH axis testing. Its stronger GH pulse amplitude compared to Ipamorelin makes it preferred in some research protocols despite its less clean side effect profile.
For long-term GH optimisation with minimal side effects, Ipamorelin is the superior choice — it produces clean GH pulses without meaningful cortisol or prolactin elevation. GHRP-2 produces a larger GH pulse but elevates cortisol and prolactin as off-target effects. GHRP-2 is preferred when maximum GH pulse amplitude is the priority over long-term use.
No — GHRP-2 should be injected fasted. Elevated blood glucose and free fatty acids suppress GH release. The pre-sleep injection should follow 2+ hours of fasting for maximum effect.
GHRP-2's prolactin elevation is generally mild and unlikely to cause gynecomastia at research doses. However, prolactin elevation combined with other aromatizable compounds (anabolic steroids) could theoretically increase risk. Monitoring prolactin levels with long-term GHRP-2 use is advisable for individuals concerned about this.
For clean long-term use: Ipamorelin. For maximum GH pulse: GHRP-2. For hunger stimulation alongside GH release: GHRP-6. Each has different applications. Most modern protocols have shifted toward Ipamorelin for its selectivity, reserving GHRP-2 for specific applications where its stronger pulse is needed.
Standard protocols use 2–3 injections daily to take advantage of multiple GH pulse windows throughout the day. Each injection should be fasted. The most important injection is pre-sleep to amplify the natural nocturnal GH pulse. Many protocols use pre-workout + pre-sleep as a 2x daily minimum.